Lori M. Waldron's practice focuses on the representation of both emerging growth and well-established public and private companies in sophisticated business transactions, with a particular emphasis on the life sciences and biotech industries. Ms. Waldron has extensive experience representing clients through all phases of their business cycles and advising them how to best take advantage of varying business opportunities, whether arising in the ordinary course of business or as an extraordinary matter. Her regular practice includes counseling her clients in connection with start-up matters (including formation issues, corporate debt and equity structure, shareholder arrangements and officer/director/employee compensation issues), angel and venture capital financings, private equity and debt investments, joint ventures and other strategic and collaborative alliances, and manufacturing and supply arrangements. Ms. Waldron also advises her clients in connection with a wide variety of complex business purchases, combinations and divestitures (including mergers, acquisitions, stock and asset sales, spin-offs, license agreements and sublicense arrangements) and general corporate matters.
Articles in the National Law Review database by Lori M. Waldron
The National Law Review recognizes Sills, Cummis & Gross as a Go-To Thought Leader for the firm’s COVID-19 coverage focusing on pandemic legislation relevant to the New York and New Jersey areas. Sills attorney – authors kept NLR readers apprised of sick leave rules, workers compensation coverage for essential workers, CARES act updates, executive orders, regional regulations and workplace restrictions. The following Sills, Cummis & Gross New York & New Jersey Coronavirus authors were exceptionally popular with the NLR readers: Grace A. Byrd, Brian A. Haskel, Jill Turner Lever, David I. Rosen, Alan E. Sherman, Jason L. Sobel and Lori M. Waldron.